PepGen reported a Q4 net loss of USD 18.3 million and a basic and diluted net loss per share of USD 0.27. R&D expenses were USD 13.9 million and G&A expenses were USD 5.9 million in Q4. For FY 2025, PepGen posted a net loss of USD 89.7 million and a basic and diluted net loss per share of USD 2.12, with R&D expenses of USD 71.0 million and G&A expenses of USD 22.6 million. Cash, cash equivalents and marketable securities totaled USD 148.5 million as of Dec. 31, 2025, which PepGen said is sufficient to fund operations into the second half of 2027. On the pipeline, PepGen said FREEDOM2 Phase 2 multiple ascending dose results from the 5 mg/kg cohort of PGN-EDODM1 in DM1 are expected in Q1 2026, while the 10 mg/kg cohort remains on track for data in 2H 2026; the company said 50% of patients (4/8) in the 10 mg/kg cohort have been dosed with up to two doses. PepGen also said it amended the FREEDOM2 protocol to provide the option to dose up to 12.5 mg/kg, received regulatory clearance to initiate FREEDOM2 in South Korea, Australia and New Zealand, and noted the FDA has placed a partial clinical hold on FREEDOM2 related to previously submitted preclinical pharmacology and toxicology studies. PepGen also said it will present unblinded final results from the Phase 1 FREEDOM-DM1 study at the 2026 MDA conference, citing Day 28 mean splicing correction of 12.3% (5 mg/kg), 29.1% (10 mg/kg) and 53.7% (15 mg/kg). Corporate updates included the appointment of Joseph Vittiglio as chief business and legal officer and the issuance of a new USPTO composition of matter patent covering PGN-EDODM1, which PepGen said is expected to provide U.S. exclusivity into the second half of 2042.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PepGen Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603041605BIZWIRE_USPR_____20260304_BW670027) on March 04, 2026, and is solely responsible for the information contained therein.
Comments